Investor Relations

A leadership story in the field of advanced cell therapy

Day High:
Day Low:
Volume:
on
Copyright West LLC. Minimum 15 minutes delayed.

Investor Relations

Press Releases

August 3, 2022

Vericel Reports Second Quarter 2022 Financial Results

July 21, 2022

Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel

July 20, 2022

Vericel to Report Second-Quarter 2022 Financial Results on August 3, 2022

Events and Presentations

Upcoming Events
More events are coming soon.

 

 

Quarterly Results

Show all

Stock Quote & Analyst Coverage

Stock Quote ()

Change
Volume
Today's Open
Previous Close
Today's High
Today's Low
52 Week High
52 Week Low
Vericel Corporation is covered by the following analysts.
Ryan Zimmerman
BTIG
Swayampakula Ramakanth
H.C. Wainwright & Co.
Jeff Cohen
Ladenburg Thalmann
Danielle Antalffy
LEERINK
Chris Cooley
Stephens
Samuel Brodovsky
Truist

Vericel Corporation is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Vericel Corporation's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vericel Corporation or its management. Vericel Corporation does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.